Clinical Trials
22 trialsNCT05537740 2026-05-20
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
Phase 1 Active not recruiting
NCT02954874 2026-05-15
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05645380 2026-04-28
NeoTRACT
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT02734290 2026-04-24
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
Phase 1/2 Active not recruiting
NCT06027268 2026-04-22
ToPCourT
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT02957968 2026-04-21
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
Phase 2 Active not recruiting
NCT03366844 2026-04-20
Breast Cancer Study of Preoperative Pembrolizumab + Radiation
Cedars-Sinai Medical Center
Phase 1/2 Active not recruiting
NCT04225117 2026-04-13
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT06604858 2026-04-07
TELESCOPE
MedSIR
Phase 2 Active not recruiting
NCT02432963 2026-01-28
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02411656 2026-01-23
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT04561362 2025-11-14
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
BicycleTx Limited
Phase 1/2 Active not recruiting
NCT03589339 2025-10-24
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Nanobiotix
Phase 1 Active not recruiting
NCT04443348 2025-10-14
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT03362060 2025-10-01
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT05382286 2025-09-18
ASCENT-04
Gilead Sciences
Phase 3 Active not recruiting
NCT04335669 2025-09-12
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Lund University Hospital
Phase 3 Active not recruiting
NCT02755272 2025-07-04
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT02644369 2025-03-26
INSPIRE
University Health Network, Toronto
Phase 2 Active not recruiting
NCT05620134 2024-10-15
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
Phase 1/2 Active not recruiting
NCT04432857 2024-06-27
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Active not recruiting